original ) (raw )A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors
Rhonda Bohn
Haemophilia, 2005
View PDFchevron_right
A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey
Doğukan Yılmaz
Journal of Medical Economics, 2005
View PDFchevron_right
Pharmacoeconomic studies of bypassing agents in mild-to-moderate bleeding episodes in patients with hemophilia and inhibitors: a critical appraisal
Erich de Paula
View PDFchevron_right
Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors
Jennifer Stephens
Current Medical Research and Opinion, 2005
View PDFchevron_right
A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors
Anne Møller Danø
Haemophilia, 2009
View PDFchevron_right
aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia – a cost‐effectiveness model
châu bùi
Vox Sanguinis, 2018
View PDFchevron_right
Impact of pharmacokinetics to reduce bleeding in a cohort of patients with severe hemophilia A in a personalized comprehensive management program
Carol Agudelo
View PDFchevron_right
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group
Alessandro Gringeri
Blood, 2003
View PDFchevron_right
A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil
M. Ozelo
Haemophilia, 2007
View PDFchevron_right
Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective
XIN YI LEE
ClinicoEconomics and Outcomes Research, 2021
View PDFchevron_right
A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand
Ellis Neufeld
Journal of managed care & specialty pharmacy, 2016
View PDFchevron_right
Physicians' Preferences Towards Coagulation Factor Concentrates in the Treatment of Hemophilia with Inhibitors: A Discrete Choice Experiment
Chris Pashos
2006
View PDFchevron_right
Cost Components of Treatment Protocols of Haemophilia Patients with Inhibitors using Bypassing Agents in Iran
Mina Golestani
Iranian Journal of Pharmaceutical Sciences, 2016
View PDFchevron_right
Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus
Giovanni Pappagallo
Journal of Clinical Medicine, 2022
View PDFchevron_right
A new modeling approach allowing prediction and comparison of the long-term outcomes of treatments for hemophilia B
Marjolijn van Keep
Journal of Comparative Effectiveness Research, 2018
View PDFchevron_right
A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A
Mart Janssen
Haematologica, 2011
View PDFchevron_right
Economic Burden of High-Responding Inhibitors in Patients with Hemophilia A in Taiwan
Thau-Ming Cham
Yonsei Medical Journal, 2013
View PDFchevron_right
Physicians’ preferences towards coagulation factor concentrates in the treatment of Haemophilia with inhibitors: a discrete choice experiment
C. Pashos
Haemophilia, 2008
View PDFchevron_right
The socio-economic burden of patients affected by Hemophilia with inhibitors
Giacomo Crotti
European Journal of Haematology, 2018
View PDFchevron_right
Cost of care of haemophilia with inhibitors
Anna Coppola
Haemophilia, 2010
View PDFchevron_right
Estimating the impact of improved management of haemophilia a on clinical outcomes and healthcare utilisation and costs
zulaiha muda
BMC Research Notes
View PDFchevron_right
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model
Konrad Maruszczyk
Journal of Medical Economics, 2021
View PDFchevron_right
A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
Roseline d'Oiron
Haemophilia, 2007
View PDFchevron_right
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
Andrea Messori
PubMed, 2018
View PDFchevron_right
Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis
Pratima Chowdary
Thrombosis and Haemostasis
View PDFchevron_right
Bypassing Agents for Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
Jamshid Salamzadeh
Iranian Red Crescent Medical Journal, 2014
View PDFchevron_right
Pharmacoeconomic Analysis of Hemophilia Care in Romania
Cristian Jinca
2020
View PDFchevron_right
Health economics of treating haemophilia A with inhibitors
Chris Knight
Haemophilia, 2005
View PDFchevron_right
Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
Dirk Garmann
Haematologica, 2019
View PDFchevron_right
The value of early treatment in patients with haemophilia and inhibitors
B. Antmen
Haemophilia, 2010
View PDFchevron_right
Clinicopathological parameters influencing inhibitor development in patients with hemophilia A receiving on-demand therapy
Namrata Punit Awasthi
Therapeutic Advances in Hematology, 2018
View PDFchevron_right
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran
Jamshid Salamzadeh
Iranian journal of pharmaceutical research : IJPR, 2016
View PDFchevron_right